TNF ANTAGONISTS

TNF binding polypeptides based on human tetranectin C-type lectin like domains (CTLD) with improved binding characteristics and improved efficacy. The polypeptides comprise a TNF binding domain having the amino acid sequence KRWS-RYF (SEQ ID NO:1). Also provided are methods of preparing the polypept...

Full description

Saved in:
Bibliographic Details
Main Authors OTTOW HELLE KROGH, MUNCH METTE, ANDERSEN MIKKEL HOLMEN, NIELAND JOSEPHUS DIRK, HOLTET THOR LAS
Format Patent
LanguageEnglish
Published 18.06.2009
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
DERIVATIVES THEREOF
ENZYMOLOGY
FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE
HUMAN NECESSITIES
HYGIENE
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
NUCLEIC ACIDS
NUCLEOSIDES
NUCLEOTIDES
ORGANIC CHEMISTRY
PEPTIDES
PHYSICS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
SUGARS
TESTING
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:TNF binding polypeptides based on human tetranectin C-type lectin like domains (CTLD) with improved binding characteristics and improved efficacy. The polypeptides comprise a TNF binding domain having the amino acid sequence KRWS-RYF (SEQ ID NO:1). Also provided are methods of preparing the polypeptides of the invention. The polypeptides may be used for the preparation of pharmaceutical compositions, and for treatment of a subject having a pathology mediated by TNF, such as treatment of rheumatoid arthritis.
Bibliography:Application Number: US20050719942